在患有晚期胃肠道 stromal 瘤的患者中,avelumab 加上 axitinib
Piotr Lukasz Rutkowski1, Anna Klimczak1, Pawel Teterycz2
1Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw 02-781, Poland.
概括
这项研究探讨了结合血管内皮生长因子 (VEGF) 和PD-L1抑制剂用于晚期胃肠瘤 (GIST) 患者. 该组合在预先治疗的GIST患者的一个子集中显示出有希望的疗效.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 胃肠道筋瘤 (GIST) 是一种疾病.
背景情况:
- 在标准铁氨酸激酶抑制剂 (TKI) 失败后,先进的胃肠道 stromal 瘤 (GIST) 患者的治疗选择有限.
- 血管内皮生长因子 (VEGF) 抑制剂具有免疫调节作用.
- 在GIST治疗中,假设VEGF和PD-L1抑制剂之间的协同作用.
研究的目的:
- 评估AVELUMAB (抗PD-L1) 与阿克西替尼 (VEGF抑制剂) 结合的疗效和安全性,用于预先治疗的高级GIST患者.
- 评估3个月无进展生存 (PFS) 的初级终点.
- 确定包括整体存活率 (OS) 和整体反应率 (ORR) 在内的二次终点.
主要方法:
- 第二阶段的AXAGIST试验.
- 招募了58名患有不可切除/转移性GIST后TKI衰竭的患者.
- 每隔2周内静脉注射10毫克/千克的阿维卢马布 (avelumab) (Q2W),每天两次口服5毫克的阿克西替尼 (axitinib).
主要成果:
- 56名患者是可评估的,53.4%的患者先前有TKI线.
- 最好的反应:8.9%的部分反应 (PR),60.7%的稳定疾病 (SD),30.4%的渐进性疾病 (PD).
- 中位数PFS为4.6个月;中位数OS为14.2个月. 57.1%实现了3个月的PFS率.
结论:
- 针对性治疗和免疫治疗的组合在预先治疗的GIST患者的一个子集中显示出有希望的疗效.
- 这种新的治疗方法需要对先进的GIST进行进一步的研究.
- 这项研究是针对预先治疗的GIST患者进行联合向治疗和免疫治疗的最大试验.
更多相关视频
07:59Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma
Published on: September 3, 2021
6.3K
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
13.7K
相关概念视频
Drugs for Treatment of Diarrhea-Predominant IBS
152
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
152
Tumor Immunotherapy
491
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
491
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
